Photo from David Steensma/X
Dec 1, 2023, 07:34
David Steensma: Fascinating to see combination trials of ruxolitinib+ reading out in myelofibrosis
David Steensma, Chief Medical Officer of Ajax Therapeutics, posted on X/Twitter:
“After so many years of involvement in HMA+ combination trials in MDS, it is fascinating to see combination trials of ruxolitinib+ reading out in myelofibrosis.”
Source: David Steensma/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 18, 2025, 07:20
Jan 18, 2025, 07:15
Jan 18, 2025, 06:41
Jan 18, 2025, 06:34
Jan 18, 2025, 00:00
Jan 17, 2025, 23:55
Jan 17, 2025, 23:47
Jan 17, 2025, 23:44